Skip to main content
. 2019 May 21;11(5):242. doi: 10.3390/pharmaceutics11050242

Figure 6.

Figure 6

Relative viability of HeLa cells after treatment with DOX and different NPs for (A) 24 h and (B) 48 h. (C) Cell viability of HeLa, A549, MCF-7, and HepG2 cells with various concentrations of BPQDs-PEG-FA. (D) Relative cell viability of HeLa cells incubated with various concentrations of BPQDs-based NPs with NIR laser irradiation (808 nm, 1 W cm−2, 10 min). (* p < 0.05, ** p < 0.01).